KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A Multicenter, Randomized, Double-Masked, Sham-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-on Corneal Crosslinking in Keratoconus Subjects 8 to 45 Years of Age: Baseline Endothelial Studies. PMID 41960981 · Cornea · 2026-Apr-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901). PMID 41956861 · Eur Urol · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 trial. PMID 41952212 · J Hematol Oncol · 2026-Apr-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Palbociclib in the Treatment of HR+/ HER2- Advanced or Metastatic Breast Cancer in Australia: A Real-World Retrospective Analysis. PMID 41952090 · Asia Pac J Clin Oncol · 2026-Apr-08 The study is a non-interventional, retrospective cohort analysis. It is not a randomized controlled trial, and there is no evidence it is a Phase III or definitive trial, as it is a real-world observational study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial. PMID 41951687 · NPJ Breast Cancer · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial. PMID 41951647 · Nat Commun · 2026-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials. PMID 41951251 · Lupus Sci Med · 2026-Apr-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Initial testing of a mobile app behavioral pain coping intervention for patients with cancer: Results of a pilot randomized controlled trial. PMID 41950509 · J Psychosoc Oncol · 2026-Apr-08 This is a pilot randomized trial in cancer patients, but it does not meet core eligibility criteria. It lacks a drug-containing intervention (interventions are behavioral pain coping via app or video). It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as the focus is on feasibility, acceptability, and pain outcomes. It is not a Phase III/IIIb or definitive Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. PMID 41955533 · J Clin Endocrinol Metab · 2026-Apr-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The PRINCE-BC trial: precision regional irradiation of nodal stations for clinical evaluation of high-risk pN0 breast cancer - a phase III, open-label, randomized controlled trial. PMID 41947078 · BMC Cancer · 2026-Apr-07 The record describes a Phase III randomized trial with a time-to-event primary endpoint (DFS) but the intervention is radiation therapy, not a drug. It is also a protocol/registration without reported results, not an original result report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 h without thrombectomy-A secondary analysis of the TRACE-III randomized trial. PMID 41944559 · Int J Stroke · 2026-Apr-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial. PMID 41914351 · J Am Heart Assoc · 2026-Apr-07 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. PMID 41712219 · JAMA · 2026-Apr-07 The study is an oncology Phase 3 randomized trial comparing two radiation therapy regimens for brain metastases. It is eligible for oncology, human, randomized, and phase criteria. However, it is excluded because the intervention is non-drug (radiation therapy only) and the primary endpoint is a patient-reported symptom score change, not a time-to-event efficacy endpoint like OS, PFS, or DFS.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Botulinum Toxin Type A in the Treatment of Primary Axillary Hyperhidrosis:A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety in Chinese Patients. PMID 41553927 · Aesthet Surg J · 2026-Apr-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial. PMID 41092464 · Aesthet Surg J · 2026-Apr-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B. PMID 41945711 · Hepatology · 2026-Apr-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Progress in management of advanced clear-cell renal cell carcinoma. PMID 41941086 · Clin Transl Oncol · 2026-Apr-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intratympanic Dexamethasone Efficacy in Preventing Cisplatin-induced Tinnitus: A Randomized Controlled Phase IIIB Clinical Trial. PMID 41940636 · Ear Hear · 2026-Apr-06 The study is a randomized, phase IIIB trial with a drug intervention in an oncology context, but the primary endpoint is the prevention of a toxicity (tinnitus), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). Therefore, it does not meet the key criterion for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and implementation of personalized postoperative care plans for gynecological oncology patients under the precision medicine paradigm: strategies to enhance patient participation and self-management capacity. PMID 41937146 · World J Surg Oncol · 2026-Apr-06 The study is a randomized oncology trial reporting time-to-event efficacy outcomes (DFS, EFS) with Kaplan-Meier analysis and HR. However, it is ineligible because the intervention is a non-drug-only behavioral/digital care pathway, and the trial phase is not explicitly identified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial. PMID 41937137 · BMC Med · 2026-Apr-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. PMID 40090937 · Chin Med J (Engl) · 2026-Apr-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative long-term sedation efficacy of remimazolam vs propofol in malignant patients with mechanical ventilation: an exploratory non-inferiority randomized study. PMID 41935116 · Sci Rep · 2026-Apr-04 The record does not meet the eligibility criteria. While it is an oncology, human, randomized, drug-intervention trial with original results, the required Phase III/IIIb or Phase II/III evidence is not established from the provided metadata. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, etc.) suitable for Kaplan-Meier digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Validating National Registry Data for Randomised Trials: Comparison of registry-derived cardiovascular events with and without adjudication in the BETAMI-DANBLOCK trial. PMID 41934630 · Eur Heart J Qual Care Clin Outcomes · 2026-Apr-04 The trial is a cardiovascular registry-based randomized trial for beta-blocker therapy in myocardial infarction patients, not an oncology study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial. PMID 41976378 · Cancers (Basel) · 2026-Apr-03 The trial is a Phase IIb randomized study (not Phase III/IIIb or Phase II/III) and its primary endpoint is an incidence rate (EAIR) of a safety/toxicity outcome (hyperglycemia), not a primary/key time-to-event efficacy endpoint like OS, PFS, etc. While efficacy is mentioned as a secondary endpoint, it is not defined as a time-to-event outcome in the abstract, nor are KM curves or HRs reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The efficacy of combined bandage contact lens and nasal margin suture fixation in pterygium patients and its impact on inflammatory cytokines. PMID 41933093 · Sci Rep · 2026-Apr-03 The study is not an oncology trial; it investigates pterygium (a benign ocular surface condition) using surgical and suture techniques, not a drug intervention for malignant neoplasms. It lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial. PMID 41932699 · BMJ Open · 2026-Apr-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Vaginal natural orifice transluminal endoscopic surgery versus laparoscopy for ovarian cystectomy: a prospective, open-label, randomized, non-inferiority pilot trial. PMID 41931151 · Arch Gynecol Obstet · 2026-Apr-03 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma. PMID 41959823 · medRxiv · 2026-Apr-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). PMID 41934038 · Eur Urol · 2026-Apr-02 The record is a letter to the editor responding to a previously published trial report. The title explicitly states 'Re:', and no abstract is provided to verify the necessary inclusion criteria. Therefore, it is not an original formal result report of a randomized trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Subarachnoid Hemorrhage: Clazosentan vs. Fasudil for Vasospasm Prevention (SAVIOR) Study: Study Protocol for a Prospective, Multicenter, Randomized Trial. PMID 41927991 · Neurocrit Care · 2026-Apr-02 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Association between screening duration and treatment outcomes in the clinical trials of ranibizumab and aflibercept for neovascular age-related macular degeneration. PMID 41927600 · Sci Rep · 2026-Apr-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial. PMID 41927289 · BMJ Open · 2026-Apr-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Anesthetic approaches and 2-year recurrence rates in non-muscle invasive bladder cancer: a randomized clinical trial. PMID 39740955 · Reg Anesth Pain Med · 2026-Apr-02 The study is an oncology RCT with time-to-event outcomes, but the intervention compares anesthesia techniques (spinal vs. general), not a drug-containing regimen. It lacks explicit Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis. PMID 41983220 · Hepatobiliary Surg Nutr · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab). PMID 41960901 · Cancer Res Commun · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Prognostic Impact of Supraclavicular Lymph Node Metastases in Lung Cancer: Do We Need a Modification of the Current Staging System? PMID 41945947 · Asian Pac J Cancer Prev · 2026-Apr-01 This is a retrospective observational study of Stage IIIB NSCLC patients receiving chemoradiation therapy. It is not a randomized trial, does not specify a drug-containing intervention, and is not a Phase III/IIIb or Phase II/III trial. It is a prognostic analysis with time-to-event endpoints (PFS, OS), but does not meet the eligibility criteria for a randomized drug trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy: A Secondary Analysis of a Cluster Randomized Clinical Trial. PMID 41941188 · JAMA Netw Open · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients: The Phase 2 MARBLE Randomized Clinical Trial. PMID 41931297 · JAMA Netw Open · 2026-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of dexmedetomidine on recovery of postoperative gastrointestinal function in patients with adhesive bowel obstruction: a single-center randomized clinical trial. PMID 41917824 · BMC Anesthesiol · 2026-Apr-01 The study is not in oncology (malignant neoplasm). It investigates postoperative GI function recovery in adhesive bowel obstruction, which is a non-malignant, non-oncologic condition. Therefore, it fails the fundamental oncology criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis. PMID 41811770 · Eur J Gastroenterol Hepatol · 2026-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial. PMID 41746630 · JAMA Oncol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial. PMID 41746629 · JAMA Oncol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension. PMID 41738079 · Am J Respir Crit Care Med · 2026-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial. PMID 41712229 · JAMA Oncol · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. PMID 41706476 · JAMA Dermatol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials. PMID 41706458 · JAMA Dermatol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study. PMID 41697690 · JAMA Neurol · 2026-Apr-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial. PMID 41677407 · Crit Care Med · 2026-Apr-01 The study is a randomized, placebo-controlled trial in septic shock, not in oncology. The primary endpoint is an inflammatory biomarker (Tumor Necrosis Factor-alpha), and while 28-day mortality is reported, it is a secondary endpoint without KM plot or HR analysis provided in the abstract. Therefore, it does not meet the core oncology or time-to-event endpoint criteria for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cognitive-Behavioral Sleep and Nutritional Intervention Enhances Recovery and Survival in Rectal Cancer Patients Undergoing Abdominoperineal Resection: A Randomized Controlled Trial. PMID 41642757 · Biopsychosoc Sci Med · 2026-Apr-01 Eligible on most criteria (oncology, human, randomized, time-to-event), but excluded because the intervention is non-drug-only (behavioral and nutritional) and no drug-containing intervention is present. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. PMID 41627802 · JAMA Intern Med · 2026-Apr-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -